Pfizer Seeks Expanded Use Of Abrysvo As Vaccine Shows Potential In 18+ Patients - Pfizer (NYSE:PFE)

Discover pivotal Phase 3 trial results for Pfizer's Abrysvo vaccine in adults 18-59 at risk of severe RSV disease. Achieved immunogenicity and safety milestones pave the way for potential regulatory approval, addressing a critical unmet need.

Related Keywords

Annaliesa Anderson ,Pfizer ,Southern Hemispheres ,